Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669304 · ClinicalTrials.gov registry record · Phase 1
Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01669304: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01669304 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01669304, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Vestibular migraine (VM) and chronic subjective dizziness (CSD) commonly cause vertigo, unsteadiness and dizziness. Clinical investigators are studying these illnesses to understand them better. VM and CSD occur together in about 1/3 of patients. That makes it hard to diagnose them accurately and decide what treatments to use. As a result, doctors and patients may be confused about these diagnoses. The goal of this study was use two different medications to tease apart the symptoms of VM and CSD. Patients who have VM and CSD together were given either verapamil or sertraline for 12 weeks. These medications are used to treat VM and CSD, though they are not approved for this purpose. Verapamil is believed to have stronger effects on symptoms of VM. Sertraline is believed to have stronger effects on symptoms of CSD. By comparing the responses of patients to these two medications, the researchers hoped to learn more about the key features of VM and CSD.
Interventions
- DRUG Sertraline
- DRUG Verapamil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669304
The ClinicalTrials.gov registry entry for NCT01669304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sertraline is the first listed.
NCT01669304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01669304 about?
NCT01669304 is a clinical study titled "Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness". Vestibular migraine (VM) and chronic subjective dizziness (CSD) commonly cause vertigo, unsteadiness and dizziness. Clinical investigators are studying these illnesses to understand them better. VM and CSD occur together in about 1/3 of patients. That makes it hard to diagnose them accurately and de...
What is the current status of trial NCT01669304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01669304?
The interventions under investigation include: Sertraline (DRUG), Verapamil (DRUG).
Who is sponsoring clinical trial NCT01669304?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.